Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori: Scratch and win

Abstract Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is generally associated with Helicobacter pylori infection and, in the great majority of patients, regresses after eradication. H. pylori-negative MALT lymphoma occurs in a small minority of cases in which treatment is based on surgery or chemoradiotherapy. In the search for H. pylori based on histology and the C13 urea breath test, this report describes a case with a series of false-negative results, thus confirming the possibility of a lower detectability of H. pylori in patients with MALT gastric lymphoma and supporting the use of additional tests in evaluating such pathology, including polymerase chain reaction. Additionally, treatment with CD20 monoclonal antibody (rituximab) is suggested as an alternative to surgery or treatment with chemotherapy or radiotherapy in patients with truly H. pylori-negative gastric MALT lymphoma

A big data platform exploiting auditable tokenization to promote good practices inside local energy communities

The Energy Community Platform (ECP) is a modular system conceived to promote a conscious use of energy by the users inside local energy communities. It is composed of two integrated subsystems: the Energy Community Data Platform (ECDP), a middleware platform designed to support the collection and the analysis of big data about the energy consumption inside local energy communities, and the Energy Community Tokenization Platform (ECTP), which focuses on tokenizing processed source data to enable incentives through smart contracts hosted on a decentralized infrastructure possibly governed by multiple authorities. We illustrate the overall design of our system, conceived considering some real-world projects (dealing with different types of local energy community, different amounts and nature of incoming data, and different types of users), analyzing in detail the key aspects of the two subsystems. In particular, the ECDP acquires data of a different nature in a heterogeneous format from multiple sources and supports a data integration workflow and a data lake workflow, designed for different uses of the data. We motivate our technological choices and present the alternatives taken into account, both in terms of software and of architectural design. On the other hand, the ECTP operates a tokenization process via smart contracts to promote good behaviors of users within the local energy community. The peculiarity of this platform is to allow external parties to audit the correct behavior of the whole tokenization process while protecting the confidentiality of the data and the performance of the platform. The main strengths of the presented system are flexibility and scalability (guaranteed by its modular architecture), which allow its applicability to any type of local energy community

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.

Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorectal cancer therapy, the determination of RAS mutational status is needed for therapeutic decision-making. Most prevalent in colorectal cancer are KRAS exon 2 mutations (40% prevalence); lower prevalence is observed for KRAS exon 3 and 4 mutations (6%) and NRAS exon 2, 3, and 4 mutations (5%). The Idylla™ KRAS Mutation Test on the molecular diagnostics Idylla™ platform is a simple (<2 minutes hands-on time), highly reliable, and rapid (approximately 2 hours turnaround time) in vitro diagnostic sample-to-result solution. This test enables qualitative detection of 21 mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS oncogene being clinically relevant according to the latest clinical guidelines. Here, the performance of the Idylla™ KRAS Mutation Assay, for Research Use Only, was assessed on archived formalin-fixed paraffin-embedded (FFPE) tissue sections by comparing its results with the results previously obtained by routine reference approaches for KRAS genotyping. In case of discordance, samples were assessed further by additional methods. Among the 374 colorectal cancer FFPE samples tested, the overall concordance between the Idylla™ KRAS Mutation Assay and the confirmed reference routine test results was found to be 98.9%. The Idylla™ KRAS Mutation Assay enabled detection of 5 additional KRAS-mutated samples not detected previously with reference methods. As conclusion the Idylla™ KRAS Mutation Test can be applied as routine tool in any clinical setting, without needing molecular infrastructure or expertise, to guide the personalized treatment of colorectal cancer patients

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.

Since the advent of monoclonal antibodies against epidermal growth factor receptor (EGFR) in colorectal cancer therapy, the determination of RAS mutational status is needed for therapeutic decision-making. Most prevalent in colorectal cancer are KRAS exon 2 mutations (40% prevalence); lower prevalence is observed for KRAS exon 3 and 4 mutations (6%) and NRAS exon 2, 3, and 4 mutations (5%). The Idylla™ KRAS Mutation Test on the molecular diagnostics Idylla™ platform is a simple (<2 minutes hands-on time), highly reliable, and rapid (approximately 2 hours turnaround time) in vitro diagnostic sample-to-result solution. This test enables qualitative detection of 21 mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS oncogene being clinically relevant according to the latest clinical guidelines. Here, the performance of the Idylla™ KRAS Mutation Assay, for Research Use Only, was assessed on archived formalin-fixed paraffin-embedded (FFPE) tissue sections by comparing its results with the results previously obtained by routine reference approaches for KRAS genotyping. In case of discordance, samples were assessed further by additional methods. Among the 374 colorectal cancer FFPE samples tested, the overall concordance between the Idylla™ KRAS Mutation Assay and the confirmed reference routine test results was found to be 98.9%. The Idylla™ KRAS Mutation Assay enabled detection of 5 additional KRAS-mutated samples not detected previously with reference methods. As conclusion the Idylla™ KRAS Mutation Test can be applied as routine tool in any clinical setting, without needing molecular infrastructure or expertise, to guide the personalized treatment of colorectal cancer patients

Comparison between results of the Idylla^™ KRAS Mutation Assay and of routine reference methods (codon level).

<p>Comparison between results of the Idylla^™ KRAS Mutation Assay and of routine reference methods (codon level).</p

Decision tree of pre-analytical FFPE sample preparation prior to Idylla^™ KRAS Mutation Assay.

<p>Decision tree of pre-analytical FFPE sample preparation prior to Idylla^™ KRAS Mutation Assay.</p

Comparison between results of the Idylla^™ KRAS Mutation Assay and of routine reference methods.

<p>Comparison between results of the Idylla^™ KRAS Mutation Assay and of routine reference methods.</p